Breaking News, Financial News

Financial Report: Gilead Sciences

Gilead Sciences

2Q Revenues: $1 billion (+53%)

2Q Earnings: $407.9 million (+54%)

YTD Revenues: $2.1 billion (+51%)

YTD Earnings: $815.3 million (+54%)

Comments: Growth in the quarter was driven by HIV product sales, up 60% to $762.2 million. Atripla, launched in July 2006 in the U.S., achieved $212.4 million in sales. Truvada sales were $385.4 million, up 29%. Also contributing to growth in the quarter were Hepsera sales, up 32% to $75.2 million, and AmBisome sales, up 16% to $64.8 million. Royalty, contract and other revenues from collaborations were $143 million, up 51% in the quarter. R&D expenses in the quarter were $135.9 million, up 50%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters